Amarillo Biosciences, Inc. Stock Other OTC
Equities
AMAR
US02301P2056
Biotechnology & Medical Research
Sales 2022 | 3.52M 4.81M | Sales 2023 | 122K 167K | Capitalization | 8.32M 11.37M |
---|---|---|---|---|---|
Net income 2022 | -14M -19.13M | Net income 2023 | -13M -17.76M | EV / Sales 2022 | 3.36 x |
Net cash position 2022 | 585K 799K | Net Debt 2023 | 3.81M 5.2M | EV / Sales 2023 | 99.3 x |
P/E ratio 2022 |
-0.6
x | P/E ratio 2023 |
-0.61
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.29% |
Managers | Title | Age | Since |
---|---|---|---|
Chun Hsien Tsai
CEO | Chief Executive Officer | 54 | 21-04-14 |
Lawrence Lin
COO | Chief Operating Officer | 55 | 21-07-31 |
Shu Ying Pan
SAM | Sales & Marketing | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yao Chung Chiang
BRD | Director/Board Member | 70 | 21-04-14 |
Pao Sheng Wei
BRD | Director/Board Member | 66 | 22-06-14 |
Chung Yi Tsai
BRD | Director/Board Member | 47 | 21-04-14 |
1st Jan change | Capi. | |
---|---|---|
-1.65% | 103B | |
+6.75% | 101B | |
+6.35% | 23.07B | |
-12.60% | 22.23B | |
-6.22% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |